Welcome to ICOD Project.
Good news from the Independent Data Monitoring Committee: A major milestone for the clinical development of AEF0217 T21RS | Webinar 27 | The European ICOD project: preliminary evidence of AEF0217 efficacy on adaptive functionality and cognition from Phase I/II studies in adults with Down syndrome Aelis Farma obtains regulatory approval for the Phase 2B trial of AEF0217 in people with Down syndrome Happy to share our third publication of @ICOD_Project, where we demonstrate that low IL-18 free levels contribute, together with high TNF-alpha and reduced TGF-β1 plasma levels, to cognitive decline in Down syndrome, and also suggest new targets to treat cognitive decline in DS!! Positive results with the clinical Phase 1/2 Study with AEF0217 in young adults with Down syndrome Our ICOD project at the European Parliament the 19th of March for the World Down Syndrome Day 2025 Aelis Farma has received a positive opinion from the EMA Pediatric Committee on the Pediatric Investigation Plan for AEF0217 in Down syndrome.Select your language
